Gilead Sciences Stock News

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are delivered directly into patients.

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now.

SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV pipeline support accelerating long-term growth, with analysts raising EPS estimates and management optimistic on margins. Despite recent gains, Gilead is still undervalued based on free cash flow ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM Eastern Time Wells Fargo Healthcare Conference on Thursday, September 4 at 11:00 AM Eastern Time Morgan Stanley Annual Global Healthcare Confere...

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth qua...

Gilead Sciences' stock surged more than 8% on Friday, as its latest earnings drew the consensus from Wall Street that the company's HIV franchise is not only holding firm but expanding, with its new prevention drug Yeztugo poised to be a catalyst for future growth.